[Morphological factors in the prognosis of the treatment results in prostatic cancer].
Investigators from the Research Institute of Oncology and Radiology (Kyrgyzstan) from 1988 to 1994 have conducted a randomized trial entering 122 patients with prostatic cancer. 44 patients received radiation treatment (group 1), 43 patients in addition to radiation were given chemotherapy and estrogens (group 2), 35 patients received drugs and estrogens (group 3). A complete response was registered in 80 (65.5%) patients. 84.2% and 69.8% of them survived 3 and 5 years, respectively. Of 30 patients 24.5%) with partial response 3- and 5-year survival was recorded in 82.8 and 57.3%, respectively. Morphological examination of transrectal prostatic biopsies 3-72 months after the treatment stated the existence of tumor pathomorphosis and unchanged tumor in 111(29.7%) and 42(11.2%) samples. It was found that the above morphological changes had developed throughout 72 months. Their intensity was the greatest within the first after-treatment year. Long-term outcomes proved better in those patients who had no residual tumor and in those who had tumor pathomorphosis during aftertreatment year 1.
Murzaliev
A D
AD
Iiazaliev
K T
KT
Abdyldaev
R A
RA
Sizikov
A I
AI
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D045166:Estradiol Congeners / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D011879:Radiotherapy Dosage; D012074:Remission Induction; D013997:Time Factors
D045166:Estradiol Congeners
Morfologicheskie faktory prognozirovaniia rezul'tatov lecheniia raka predstatel'noĭ zhelezy.